Primary plasma cell leukemia with complex karyotype: report of one case and review of literature
10.3760/cma.j.cn115356-20200321-00075
- VernacularTitle:伴复杂核型的原发性浆细胞白血病一例并文献复习
- Author:
Juan WANG
1
;
Lijie LIANG
;
Yuzhang LIU
;
Lina LIU
;
Yaomei WANG
;
Pu XIANG
;
Baijun FANG
;
Yongping SONG
Author Information
1. 郑州大学附属肿瘤医院 河南省肿瘤医院血液科 450008
- From:
Journal of Leukemia & Lymphoma
2020;29(7):419-422
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy of the serial treatment with autologous hematopoietic stem cell transplantation after bortezomib and dexamethasone-based triple chemotherapy regimen and followed by lenalidomide and intermittent intensive therapy in primary plasma cell leukemia.Methods:A retrospective analysis was made on the clinical data of one patient who was diagnosed as primary plasma cell leukemia with complex karyotype in April 2018 in Henan Cancer Hospital, and the relevant literature was reviewed.Results:The patient received multiple cycles of bortezomib and dexamethasone-based triple chemotherapy regimen, then received autologous hematopoietic stem cell transplantation, lenalidomide and intermittent intensive therapy. The patient eventually achieved complete remission and the progression-free survival time was 18 months until the day before the deadline for this article.Conclusion:The treatment with autologous hematopoietic stem cell transplantation after bortezomib and dexamethasone-based triple chemotherapy regimen and followed by lenalidomide and intermittent intensive therapy may improve the prognosis of patients with primary plasma cell leukemia and prolong the survival time.
